First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer

Thürlimann, B.B.ThürlimannBeretta, K.K.BerettaBacchi, M.M.BacchiCastiglione, MonicaMonicaCastiglioneGoldhirsch, A.A.GoldhirschJungi, W. F.W. F.JungiCavalli, F.F.CavalliSenn, H.-J.H.-J.SennFey, MartinMartinFeyLöhnert, T.T.Löhnert2024-10-252024-10-251996https://boris-portal.unibe.ch/handle/20.500.12422/161463en600 - Technology::610 - Medicine & healthFirst-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancerarticle10.7892/boris.11580710.1093/oxfordjournals.annonc.a010635